A phase I/II open-label platform study to evaluate the safety and efficacy of multiple amivantamab-based therapeutic combinations in participants with advanced, unresectable lung cancer : A phase I/II open-label platform study to evaluate the safety and efficacy of multiple amivantamab-based therapeutic combinations in participants with advanced, unresectable lung cancer

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 20. Juni Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Unresectable metastatic non-small cell lung cancer Cancer
Phase: Phase 1/Phase 2
Recruitment Status: Recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-02-2023, Last updated: 2023-06-29

ICTRP ID:

ISRCTN23584582
2022-000485-18
NCT05488314
61186372PANSC2001
IRAS 1006057

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WHO009023747